CF PHARMTECH (02652): NMPA accepts the application for the marketing authorization of budesonide nasal spray.

CF PHARMTECH (02652) announced that the company's application for the market approval of budesonide nasal spray has been accepted by the National Medical Products Administration of the People's Republic of China. Nasal spray is a complex formulation with high technological barriers. With the nasal drug delivery technology platform, the company has established a comprehensive product matrix covering a variety of indications and the entire treatment course management of respiratory and nasal inflammation. The company's existing product portfolio in this area includes: - Montelukast Fluticasone Propionate Nasal Spray (ShufeiMin): The first domestic antihistamine-corticosteroid nasal spray, included in the "National Medical Insurance Drug Catalog" in 2023; - Mometasone Furoate Nasal Spray: First-line drug for allergic rhinitis in adults and children aged 3 and above; - Budesonide Nasal Spray (the product in question): For patients aged 6 and above, targeting seasonal acute attacks, year-round maintenance therapy, and nasal polyps; and - Olopatadine/Mometasone Nasal Spray: For adolescents aged 12 and above and adults with moderate to severe allergic rhinitis symptoms. The acceptance of the application for budesonide nasal spray further enriches the company's product pipeline in the field of allergic rhinitis, demonstrating the company's determination and capability to deepen its layout in the field of respiratory system inhalation therapy, providing patients with high-quality treatment options. The group will actively communicate with the NMPA and advance the subsequent review process in accordance with regulatory requirements.